HHS Secretary Robert F. Kennedy Jr. signed a Public Readiness and Emergency Preparedness (PREP) Act declaration extending liability protections for manufacturers and distributors of favipiravir, an experimental antiviral drug being developed as a potential treatment for the Andes hantavirus strain. The protections, extended through July 18, shield companies from civil liability related to the manufacture, testing, distribution, and administration of the drug during the declared public health emergency. The PREP Act grants the HHS Secretary broad authority to invoke liability protections during health emergencies without requiring explicit congressional approval.

The decision directly affects pharmaceutical manufacturers and distributors involved in favipiravir development and distribution, insulating them from lawsuits by patients who may experience adverse effects from the experimental treatment. Patients and their families seeking legal recourse for injuries potentially linked to the drug face significant barriers under PREP Act immunity. Healthcare providers administering the treatment and patients receiving it as an emergency measure are exposed to health risks without traditional legal remedies available in non-emergency contexts.

This action reflects a pattern within the Kennedy-led HHS of prioritizing pharmaceutical company protections during public health emergencies, a framework that echoes the Trump administration's previous use of emergency declarations to restrict liability and accelerate pharmaceutical development with limited safety oversight. The decision mirrors the administration's broader approach to health emergencies as justification for expanded executive authority and reduced regulatory scrutiny, similar to how travel restrictions have been employed as immigration policy tools under the guise of disease containment.

The action prompted backlash from Kennedy's base supporters in the 'Make America Healthy Again' movement, who view pharmaceutical liability immunity with suspicion and advocate for stronger safety testing and corporate accountability. This internal conflict highlights tensions within the administration between pro-business pharmaceutical policies and anti-establishment health skepticism. Reversal would require Kennedy to rescind the PREP Act declaration or Congress to legislatively narrow PREP Act authority, though both pathways face political obstacles.